Inhibition of epidermal growth factor receptor signaling pathway by delphinidin, an anthocyanidin in pigmented fruits and vegetables

International Journal of Cancer

Volumn 123, Issue 7, 2008, Pages 1508-1515

  Afaq, Farrukh ^a   Zaman, Najia ^a   Khan, Naghma ^a   Syed, Deeba N ^a   Sarfaraz, Sami ^a   Zaid, Mohammad Abu ^a   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Apoptosis; Breast cancer; Delphinidin; Epidermal growth factor receptor; Mitogen activated protein kinases

Indexed keywords

ANTHOCYANIN; BETA ACTIN; CASPASE 3; DELPHINIDIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL GROWTH; CELL IMMORTALIZATION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FRUIT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VEGETABLE; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG ANTAGONISM; DRUG EFFECT; GENE SILENCING; GENETICS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTHOCYANINS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; ENZYME ACTIVATION; FRUIT; GENE SILENCING; HUMANS; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VEGETABLES;

EID: 50549092185     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23675     Document Type: Article

References (29)

1. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
2. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16.
3. Yarden Y, Sliwkowski MX. Untangling the erbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
4. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43:481-9.
5. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70.
6. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999;17:259-69.
7. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
8. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004;91:1532-42.
9. Goldman R, Levy RB, Peles E, Yarden Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 1990;29:11024-8.
10. Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003;63:1-5.
11. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
12. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005;8:287-97.
13. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
14. Costa S, Stamm H, Almendral A, Ludwig H, Wyss R, Fabbro D, Ernst A, Takahashi A, Eppenberger U. Predictive value of EGF receptor in breast cancer. Lancet 1988;2:1258.
15. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59.
16. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-44.
17. Afaq F, Syed DN, Malik A, Hadi N, Sarfaraz S, Kweon MH, Khan N, Zaid MA, Mukhtar H. Delphinidin, an anthocyanidin in pigmented fruits and vegetables, protects human HaCaT keratinocytes and mouse skin against UVB-mediated oxidative stress and apoptosis. J Invest Dermatol 2007;127:222-32.
18. Oak MH, Bedoui JE, Madeira SV, Chalupsky K, Schini-Kerth VB. Delphinidin and cyanidin inhibit PDGF(AB)-induced VEGF release in vascular smooth muscle cells by preventing activation of p38 MAPK and JNK. Br J Pharmacol 2006;149:283-90.
19. Rahman MM, Ichiyanagi T, Komiyama T, Hatano Y, Konishi T. Superoxide radical- and peroxynitrite-scavenging activity of anthocyanins; structure-activity relationship and their synergism. Free Radic Res 2006;40:993-1002.
20. Lamy S, Blanchette M, Michaud-Levesque J, Lafleur R, Durocher Y, Moghrabi A, Barrette S, Gingras D, Béliveau R. Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. Carcinogenesis 2006;27:989-96.
21. Martin S, Favot L, Matz R, Lugnier C, Andriantsitohaina R. Delphinidin inhibits endothelial cell proliferation and cell cycle progression through a transient activation of ERK-1/-2. Biochem Pharmacol 2003;65:669-75.
22. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7 (Suppl 4):2-8.
23. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
24. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
25. Lorch JH, Thomas TO, Schmoll HJ. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 2007;67:727-34.
26. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007;282:14845-52.
27. Khan N, Afaq F, Mukhtar H. Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis 2007;28:233-9.
28. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-85.
29. Xiao X, Wu J, Zhu X, Zhao P, Zhou J, Liu QQ, Zheng L, Zeng M, Liu R, Huang W. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 2007;121:2095-104.